Market Overview

Canaccord Says The Nellix 'Carrot' Should Drive Endologix Higher

Share:
Canaccord Says The Nellix 'Carrot' Should Drive Endologix Higher

Shares of Endologix, Inc. (NASDAQ: ELGX) rose more than 6 percent after Canaccord Genuity upgraded the stock to Buy from Neutral, saying that the Nellix "carrot" could be the key driver both this year and next.

Nellix is an investigational EndoVascular Aneurysm Sealing (EVAS) system designed for the treatment of infrarenal abdominal aortic aneurysm (AAA).

Rating And Justification

"We upgrade ELGX to BUY, as we think the firm has robust momentum coming out of SVS (where full NELLIX US IDE data were presented) and heading into H2:16/2017 (when NELLIX will hit the US market)," analyst Jason Mills wrote in a note.

The analyst expects "higher, pre-Nellix consumption of Ovation & AFX2 as doctors seek a favorable place in queue for Nellix training" amid perceived robust demand for Nellix upon approval.

Related Link: Endologix Reveals Positive Clinical Data From Nellix EVAS Forward-IDE Study

Mills estimates Endologix's organic top-line growth rate through 2018 will approximate 20 percent, and also notes gross margins are starting to re-accelerate.

The analyst highlighted revenue growth and gross margin as the two highest correlated variables to multiple expansion in small-cap med-tech, according to Canaccord's regression analysis.

The analyst anticipates the Nellix U.S. ramp will be much faster than Europe's ramp, and anticipation should drive share gain via new customers adopting Ovation/AFX2 within the near term.

Bottom Line

"In sum, we anticipate an accelerating momentum in ELGX accounts ahead of US NELLIX approval. This should show up in H2:16 quarterly results, providing further ammunition for the stock heading into the FDA approval announcement, which we continue to anticipate before year-end 2016E," Mills added.

Mills raised the price target to $15.50 from $11.25 and increased 2017 revenue estimate to $243 million up from $231 million. For 2016, the analyst still expects a loss of $0.77 and revenue of $200.7 million.

At the time of writing, shares of Endologix rose 5.52 percent to $13.38.

Latest Ratings for ELGX

DateFirmActionFromTo
Aug 2018MaintainsMarket PerformMarket Perform
Aug 2018DowngradesOverweightNeutral
May 2018MaintainsHoldHold

View More Analyst Ratings for ELGX
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Upgrades Health Care Price Target FDA Analyst Ratings Trading Ideas Best of Benzinga

 

Related Articles (ELGX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
NVDACascendMaintains220.0
ADBECleveland ResearchInitiates Coverage On283.0
IMOCiBCUpgrades
RETAJefferiesMaintains254.0
SNAPAreteUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

'Nashville' And 4 Other Shows That Were Saved After Cancellation

Twitter Rallies Off Social M&A